Transcript
A (0:00)
Biotech Daily is now open for sponsors and job of the week listings. If you want to reach biotech or pharma operators, scientists, founders and investors, you can book a single episode, a full week or promote an open role, all directly by visiting sponsor O with AI that's sponsor OWITH AI.
B (0:19)
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we close out the year 2025, it's clear that the pharmaceutical and biotech industries have experienced a period of significant transformation. This year has been marked by groundbreaking drug approvals, strategic partnerships and a focus on innovative therapies that promise to redefine patient care. One of the standout achievements this year comes from GlaxoSmithKline, which received approval from the US FDA for its ultra long acting biologic extensure aimed at treating severe asthma with an eosinophilic phenotype in adolescents and adults. This approval underscores the growing trend toward personalized medicine and biologics, offering new hope for patients with chronic respiratory conditions by providing more sustainable and personalized treatment options. In the oncology sector, Merx keytruda and Astellas pharmaspadsiv have demonstrated significant overall survival benefits when used as perioperative treatments for cisplatin eligible muscle invasive bladder cancer. This combination therapy of a PD1 checkpoint inhibitor and an antibody drug conjugate highlights the evolving landscape of cancer treatment, emphasizing the role of immunotherapy and targeted therapies in improving patient outcomes in challenging cancer subtypes. However, not all developments have been positive. Hanza Biopharma faced challenges with its kidney transplant drug imlifidase. Despite success in kidney transplant trials, it failed to achieve desired results in treating antiglomerular basement membrane disease. This serves as a reminder of the complexities involved in drug repurposing efforts within autoimmune diseases. Alnilam Pharmaceuticals announced a significant investment to enhance its Norton, Massachusetts facility into a dedicated site for small interfering RNA production. This move reflects the industry's shift towards RNA based therapies that offer targeted gene silencing capabilities and positions Alnilam at the forefront of RNA therapeutics production. In another promising development, Immunity Bio reported positive Data from its Quilt 3.032 study on Anktiva for BCG unresponsive non muscle invasive bladder cancer with high grade papillary disease. The potential expansion of Anktiva's use reinforces the importance of personalized immunotherapies in oncology. The launch of Ambros Therapeutics, with $125 million in Series A funding, highlights efforts to develop non opioid pain medications already approved abroad. This initiative addresses chronic pain management without relying on opioids, potentially advancing analgesic therapies. Amidst the ongoing opioid crisis in China. Fosun Pharma's acquisition of a majority stake in Green Valley Pharmaceuticals aims to revive a controversial seaweed derived Alzheimer's medication despite skepticism over its efficacy. This investment signals continued innovation efforts amid growing demand for effective Alzheimer's treatments. Siemens Healthineers partnership with Alzipath to incorporate PTA U217 antibodies into its Autelica immunoassay platforms marks a significant step forward in Alzheimer's diagnostics. This collaboration aims to enhance biomarker detection capabilities crucial for early diagnosis and intervention strategies in neurodegenerative diseases. On the strategic front, Bristol Myers Squibb entered into a substantial research agreement with Harbor Biomed valued at up to $1.1 billion. This deal underscores Big Pharma's ongoing pursuit of alliances to advance therapeutic pipelines and antibody technologies. Finally, Sencora's acquisition of One Oncology for $5 billion underscores consolidation trends within specialty practice networks by valuing One Oncology at $7.4 billion. This acquisition reflects the growing importance of integrated oncology care models and collaborative networks in enhancing patient care delivery. As we examine these developments collectively, they illustrate dynamic progressions within pharma and biotech sectors emphasizing precision medicine, innovative therapeutic modalities like RNA and immunotherapies, strategic collaborations and efforts to tackle complex diseases like cancer and Alzheimer's. In clinical trials news, Nectar Therapeutics reported nuanced success during phase 2 trials targeting interleukin 2 for severe alopecia areata treatment following adjustments made concerning patient inclusion criteria, highlighting how patient selection can significantly influence trial outcomes while underscoring precision medicine approaches importance. Addition Therapeutics emerged from stealth with $100 million funding aiming to revolutionize genetic medicine via breakthrough print technology, reflecting trends where academic institutions serve as innovation hubs fueling biotech advancements. Overall, these stories highlight strategic movements across these industries as they close out 2025, demonstrating how large pharmaceutical companies continue broadening pipelines through alliances with biotech firms aimed at harnessing innovative therapeutics.